Volunteer for NIAID-funded clinical studies related to Dengue Fever on ClinicalTrials.gov.
One small RNA regulates mosquito development, growth and reproduction. Read more about how removing it could reduce rates of dengue.
Learn how NIAID is working to stop mosquito-borne diseases.
Early diagnosis and treatment of dengue is critical as epidemics of the disease become larger and more frequent. An estimated 50 to 100 million people contract dengue each year in over 100 countries. Left untreated, patients may experience hemorrhage and shock, leading to death.
Recognizing the threat to public health posed by dengue, NIAID is funding nearly 60 dengue research projects, including studies on dengue hemorrhagic fever and dengue shock syndrome, the most severe forms of the disease. NIAID research priorities include effective community-based prevention programs, improved laboratory-based international surveillance, rapid diagnostic tests and therapies, and development of and clinical trials for dengue vaccines. Learn more about NIAID's dengue fever research.
NIH-Developed Candidate Dengue Vaccine Shows Promise in Early-Stage Trial—Jan. 23, 2013
Media Availability: NIH Scientists Discuss Opportunities for Dengue Research in the Americas—July 10, 2012
Media Availability: NIH Grantees Find Dengue Affects Genes, Function of Mosquito Salivary Glands—March 29, 2012
Scientific Meeting: A Re-Emerging Challenge in the Americas: Opportunities for Dengue Research Collaboration—Feb. 16-18, 2011
All Dengue Fever News Releases
News from NIAID-Supported Institutions
Dr. Richard Kuhn of Purdue University provided the image of a dengue virion used in the banner above.
Last Updated January 23, 2013